KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Gross Profit (2018 - 2025)

Castle Biosciences' Gross Profit history spans 7 years, with the latest figure at $68.7 million for Q4 2025.

  • For Q4 2025, Gross Profit fell 2.04% year-over-year to $68.7 million; the TTM value through Dec 2025 reached $273.2 million, changed 0.49%, while the annual FY2025 figure was $273.2 million, 0.49% changed from the prior year.
  • Gross Profit for Q4 2025 was $68.7 million at Castle Biosciences, up from $64.3 million in the prior quarter.
  • Across five years, Gross Profit topped out at $72.5 million in Q2 2024 and bottomed at $19.1 million in Q2 2021.
  • The 5-year median for Gross Profit is $44.6 million (2023), against an average of $45.4 million.
  • The largest annual shift saw Gross Profit surged 86.33% in 2023 before it decreased 8.31% in 2025.
  • A 5-year view of Gross Profit shows it stood at $20.4 million in 2021, then surged by 40.97% to $28.8 million in 2022, then skyrocketed by 86.33% to $53.7 million in 2023, then soared by 30.6% to $70.1 million in 2024, then fell by 2.04% to $68.7 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Gross Profit are $68.7 million (Q4 2025), $64.3 million (Q3 2025), and $68.6 million (Q2 2025).